Portfolio
The companies we back.
A focused set of biotech ventures spanning oncology and adjacent frontiers — backed from discovery into the clinic.
Portfolio
Our focus shows in who we back.
Every company we've backed since 2016, spanning oncology and the areas around it. Filter by stage to see where each stands today.
Arcus Biosciences
ORIC Pharmaceuticals
Werewolf Therapeutics
Harpoon Therapeutics
Halda Therapeutics
Orna Therapeutics
Dren Bio
Anavo Therapeutics
Breakpoint Therapeutics
cellvie
Cullinan
Delphia Therapeutics
Epi Biologics
Incendia Therapeutics
LiberoThera
Light Horse Therapeutics
Magnet Biomedicine
NextCure
Normunity
STORM Therapeutics
Theo
Transition Bio
VerteroNo companies match that filter.
Behind the roster
The mandate is narrow on purpose.
We invest from preclinical through proof of concept, across oncology, immunology and allergy, urology, bone and muscle, and orphan disease — in small molecules and biologics, with gene and cell therapy taken opportunistically.
See the investment mandate